Clinical Trial Update: A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major [Phase 1]

View source ↗

Summary

Phase 1 safety and efficacy study of CS-101 in beta-thalassemia major has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta Thalassemia Major

Drugs mentioned

• CS-101

Snippet

Sponsor: CorrectSequence Therapeutics Co., Ltd | Conditions: Beta-Thalassemia Major | Phase 1 | Status: COMPLETED